Untitled

CanCURE 2.0

Principal Investigators

 

Éric A. Cohen, PhD

CanCURE 2.0 Lead Investigator

 

Theme 2 & 3 Participant

​

​

Petronela Ancuta, PhD

Jean-Pierre Routy, MD

Theme 3 Co-Leader

Theme 2 Participant

Co-Investigators

Haddad-Elie.png

Élie Haddad, MD, PhD

Cecilia Costiniuk, MD

Theme 2 Participant

Lead on the McGill Autopsy Biobank Initiative

Theme 2 & 3 Participant

Emilia Liana Falcone, MD

Theme 1 & 3 Participant

Bill Cameron, MD, FRCPC, FACP

Theme 3 Participant

Mohammad-Ali Jenabian DVM, PhD

Theme 1 & 2 Participant

Christopher Power, PhD

Theme 2 Participant

Theme 1& 2 Participant

Steering Committee

CanCURE 2.0's Steering Committee (SC) includes the Team's seven Principal Investigators, as well as two Principle Knowledge Users that oversee and provide the community perspective. The SC is responsible for the overall management of the program and for setting scientific and training priorities.

 

Keith Fowke,

 PhD

Theme 1 Participant

Lead of Mentoring & Training Program

Mario A.

Ostrowski,MD

Theme 1 & 3 Participant

Lead on Autopsy Biospecimens & New Inhibitor Studies

Thomas T. Murooka, PhD

Theme 1 Co-Leader

 

​

SC members include:

Éric Cohen, SC Co-Chair, CanCURE 2.0 Lead Investigator, Principal Investigator

Jonathan Angel, SC Co-Chair, Principal Investigator

Petronela Ancuta, Principal investigator

Jérôme Estaquier, Principal Investigator

Thomas Murooka, Principal Investigator

Nicolas Chomont, Principal investigator

Jean-Pierre Routy, Principal Investigator

Ron Rosenes, Principle Knowledge User

Shari Margolese, Principle Knowledge User

​

 

Eric J. Arts, PhD

Professor and Chair, Department of Microbiology and Immunology, Schulich School of Mecidine & Dentistry, Western University, London, On, Canada
Director, Ugandan CFAR Laboratories

Michael M. Lederman,MD

​

Scott R. Inkley Professor of Medicine, Professor of Pathology, Microbiology, Molecular Biology and Biomedical Ethics, School of Medicine, Case Western Reserve University, Cleveland, Oh, United States

Guido Poli, MD

Professor and Head, AIDS Immunopathogenesis Unit, Division of Immunology, Transplantation and Infectious Diseases, Vita-Salute San Raffaele University School of Medicine & San Raffaele Scientifuc Institute, Milan, Italy

E Arts_pic 2_edited.jpg

Guido Silvestri, MD

Eminent Scholar in Comparative Pathology, Georgia Research AllianceProfessor of pathology and Laboratory Medicine, School of Medicine, Emory University, Chief, Division of Microbiology & Immunology, Yerkes National Primate Research Center, Atlanta, GA, United States

Scientific Advisory Board

CanCURE 2.0 is guided by a Scientific Advisory Board comprising four world-renowned basic and clinical scientists with a proven track record in the field of HIV Cure research.

Principle Knowledge Users

 

Shari Margolese

Principle Knowledge User

Ron Rosenes

Principle Knowledge User

Community Advisory Board

Keresa Arnold

Research Coordinator, ACCHO

Renee Mashing

Community Advisor

José Sousa

Community Advisor

​

Darien Taylor

Community Health Advocate

Wangari Tharao

Community Advisor

Charlotte Guerlotté

Community-Based Research Coordinator

Anita Del Corpo

Project Manager

Team Coordination

 

Partners

 

Clinical Trial Network

The CIHR Canadian HIV Trials Network (CTN) is an innovative partnership of clinical investigators, physicians, nurses, people living with HIV, pharmaceutical manufacturers and others that facilitate HIV clinical trials of the highest scientific and ethical standards.

ViiV Healthcare

Born out of a partnership between GSK and Pfizer in 2009, with Shionogi joining in 2012, ViiV Healthcare is determined to help end the HIV epidemic. Their one focused goal unites 1100 employees located across over 20 countries, with their expertise in research, manufacturing, policy and more. Viiv's current portfolio of 14 HIV treatments is thier first step in fighting back against the disease. ViiV Healthcare is dedicated to widening access to ensure those who need their medicines can receive them. Collaborations with organisations such as IAS, CHAI and MPP enable their medicines to make the greatest possible impact in countries around the world. 

Gilead

Gilead's focuses on advancing the care of patients through its research and development efforts directly impacts our relationships with physicians, patients and their caregivers, and our employees. They provide physicians with the resources to better care for their patients by rapidly and efficiently discovering and developing innovative therapeutics. They collaborate with patient advocates, design drugs to enhance treatment regimens and implement effective patient assistance programs to ensure our efforts help meet the needs of patients and their caregivers.

Theratechnologies is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV.

Theratechnologies

Biolegend

BioLegend is a leading developer of cutting-edge antibodies and reagents provided for biomedical research worldwide. Their objective is to accelerate research and discovery by offering the highest quality products at an outstanding value, along with superior customer service and technical support. 

Merck

Merck's vision is to make a difference in the lives of people globally through their innovative medicines, vaccines, and animal health products. They are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.

Affiliated Universities & research centers

©2021 CanCURE

Follow

  • https://twitter.com/cancurehiv
  • White Facebook Icon
  • White YouTube Icon
  • White LinkedIn Icon